Form 4: Nurix Therapeutics Director, Lori Anne Kunkel, Reports Stock Option Grant
SEC Form 4
Director Lori Anne Kunkel reports receiving a stock option grant for 25,000 shares of Nurix Therapeutics, Inc.
Summary
- Lori Anne Kunkel, a director of Nurix Therapeutics, Inc. [NRIX], filed a Form 4 on May 19, 2025.
- The report details the grant of a stock option to purchase 25,000 shares of common stock at an exercise price of $9.51.
- The option vests 100% on the earlier of the next annual meeting of the Issuer's stockholders or May 19, 2026, subject to continued service.
- The options expire on 05/18/2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about a stock option grant.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector, to align their interests with shareholders and incentivize long-term growth.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- The size of the grant (25,000 shares) would need to be compared to grants made to directors at similarly sized biotech companies to determine if it is within the typical range.
- Companies like Amgen, Gilead, and Biogen often use stock options as part of their compensation strategy for board members.
Stakeholder Impact
- The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of the transaction (stock option grant) and filing of Form 4. |
| 05/19/2026 | Date of full vesting of the stock option (or earlier at the next annual meeting). |
| 05/18/2035 | Expiration date of the stock option. |
Keywords
Form 4, stock option, Nurix Therapeutics, NRIX, director, Kunkel, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.